-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Esophageal cancer is one of the most common cancers in the world, with an overall five-year survival rate of less than 20%, making it the seventh leading cause of cancer-related deaths.
advanced esophageal cancer, which does not spread far away, is mostly treated with surgical excision, which is performed by minimally invasive esophageal excision (MIE) and open thoracic esophageal excision (OE).
study aims to compare the five-year survival rates of patients with esophageal cancer after surgery.
study, a population-based queue study, included almost all patients who received a select esophageal cancer excision in Sweden or Finland between 2010 and 2016, followed up until 2020.
1,264 patients, 470 (37.2%) received MIE and 794 (62.8%) received OE.
compared to OE, MIE is associated with an 18% reduction in 5-year all-cause mortality (correction risk ratio of 0.82, 95% CI 0.67-1.00; P=0.048).
HR was 0.87 (95% CI 0.68-1.11) compared to the five-year all-cause mortality rate after OE, while the total MIE was lower than the post-OE all-cause mortality correction HR, at 0.77 (0.60-0.98).
, the study showed that patients with esophageal cancer treated with MIE had significantly higher five-year survival rates than those treated with OE, and that full MIE had greater benefits for survival prognosis than mixed MIE.
